FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Evidence visual
Semaglutide evidence and risk matrix
intermediate researcher fit
Evidence
Tier A
Risk
medium
Regulatory
rx approved
WADA
none
FDA
flagged
Route
subcutaneous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Semaglutide is a long-acting GLP-1 receptor agonist used clinically for type 2 diabetes and obesity. Human evidence is robust, with major randomized trials showing meaningful weight loss and glycemic improvement. Key caveat: FDA has warned about compounded semaglutide quality, dosing, and counterfeit product risks, so retail research-vial assumptions should not be treated as equivalent to approved products.
Decision path
Where Semaglutide fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Semaglutide belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GLP-1 receptor agonist that increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and increases satiety.
subcutaneous, oral
Approved human use: 0.25 mg to 2.4 mg weekly subcutaneous; oral semaglutide 3 mg to 14 mg daily.
Clinically meaningful appetite reduction, HbA1c improvement, and substantial body-weight reduction in approved-use populations.
Glucose effects emerge over the first weeks; weight-loss effects build across 3 to 12 months.
Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, severe gastroparesis, pregnancy, and concurrent insulin/sulfonylureas.
Common GI adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder and pancreatitis concerns exist, and thyroid C-cell tumor warning remains part of class labeling.
Additive hypoglycemia risk with insulin or sulfonylureas. Delayed gastric emptying can alter absorption timing for oral drugs.
Cost at a glance
Typical cycle cost
$120.00
Estimated monthly
$120.00
Protocol style
Continuous / ongoing
Continuous
Estimate confidence
High confidence
Assumes roughly 4 mg–10 mg per cycle, using 1 tracked affiliated listing.
GLP-1 use is better treated as ongoing monthly therapy than a finite cycle.
Age, sex, and monitoring
Life-stage fit
Strongest fit for adults where weight, glucose control, and cardiometabolic risk are part of the decision.
Best fit age ranges: 35-44, 45-54, 55-64
Sex-specific note
GLP-1 therapies are broadly relevant across sexes, but some reviews suggest women may see stronger average weight-loss response.
female
Avoid in pregnancy or active conception planning unless a clinician specifically directs otherwise.
Monitoring burden
mediumMetabolic follow-up and GI tolerance matter more than exotic monitoring, but this is still not a zero-friction compound.
Baseline labs and checks
CMP, fasting glucose or HbA1c, lipids, weight and blood pressure baseline
Follow-up cadence
Early tolerance review in the first weeks, then metabolic follow-up every few months.
Red flags
- persistent vomiting or dehydration
- gallbladder symptoms
- pancreatitis-type abdominal pain
Known Interactions
Do not layer GLP-1 / dual-incretin agonists in a consumer stack; GI burden and dosing complexity rise without a clear rationale.
Two GLP-1 agonists in the same stack creates redundant mechanism and higher side-effect burden.
Approved GLP-1 therapy should not be layered with an investigational multi-incretin agent.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Semaglutide.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.